B
Bull
Bull · 25%PHVS
$32.16
Scenario price
$27.740
-1.778 (-6.41%)At close
Loading chart…
- High
- 29.540
- Open
- 29.500
- VWAP
- 28.32
- Volume
- 1.31M
- Mkt Cap
- 969.24M
- Low
- 27.680
- Amount
- 37.03M
- EV/EBITDA, TTM
- 0.00
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
AI analysis of Pharvaris NV (PHVS)
BuyPharvaris NV (PHVS) is a good buy right now due to its recent clinical trial success, which has driven analyst price targets significantly higher, with the average target around $54. Additionally, the stock is currently priced at $27.74, which is well below the lowest analyst target of $40, suggesting substantial upside potential. However, the main risk is the company's ongoing net losses, which amounted to €47.8 million in the last quarter, indicating financial instability that could affect future performance.
Valuation Metrics
The current forward P/E ratio for Pharvaris NV (PHVS) is 0.00, compared to its 5-year average forward P/E of -6.58.
Alphio AI Price Scenarios for PHVS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding PHVS
Events Timeline
News
9.509-09NASDAQ.COMPharvaris N.V. Phase 3 Trial Success for Deucrictibant
5.009-09stocktwitsBioCryst's Orladeyo Approved for HAE Attack Prevention
9.509-08stocktwitsRoivant and Pharvaris Achieve Clinical Trial Success
9.509-08Yahoo FinanceBiotech Stocks Hit All-Time Highs Following Positive Trial Results
9.009-08NASDAQ.COMPharvaris Reports Positive Results for HAE Treatment
PHVS FAQ — answered by Alphio AI
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet. It operates in the Healthcare sector.
Pharvaris NV (PHVS) is a good buy right now due to its recent clinical trial success, which has driven analyst price targets significantly higher, with the average target around $54. Additionally, the stock is currently priced at $27.74, which is well below the lowest analyst target of $40, suggesting substantial upside potential. However, the main risk is the company's ongoing net losses, which amounted to €47.8 million in the last quarter, indicating financial instability that could affect future performance.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.